Temozolomide (NSC 362856), DNA Alkylator
Descrição
Temozolomide (NSC 362856) is an oral active DNA alkylating agent that crosses the blood-brain barrier. Temozolomide is also a proautophagic and proapoptotic agent. Temozolomide is effective against tumor cells that are characterized by low levels of O6-alkylguanine DNA alkyltransferase (OGAT) and a functional mismatch repair system. Temozolomide has antitumor and antiangiogenic effects. - Mechanism of Action & Protocol.
Temozolomide in paediatric high-grade glioma: a key for combination therapy?
Biomedicines, Free Full-Text
Current and future developments in the use of temozolomide for the treatment of brain tumours - The Lancet Oncology
Temozolomide
Temozolomide 85622-93-1 wiki
Temozolomide, C6H6N6O2
Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas, BMC Cancer
Molecules, Free Full-Text
Polymer–Temozolomide Conjugates as Therapeutics for Treating Glioblastoma
T1178-50mg Temozolomide [85622-93-1] Hexabiogen
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules
Selleck Chemical LLC Temozolomide 25mg 85622-93-1 CCRG81045, NSC 362856,TMZ
Efficient delivery of Temozolomide using ultrasmall large-pore silica nanoparticles for glioblastoma - ScienceDirect
de
por adulto (o preço varia de acordo com o tamanho do grupo)
